menu
    • menu
    [{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Endoxifen","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"AT-H201","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Atossa Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"AT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Atossa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Atossa Therapeutics \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Endoxifen","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Endoxifen","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"(Z)-endoxifen","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atossa Therapeutics \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Z-endoxifen","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atossa Therapeutics \/ Atossa Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Z-endoxifen","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Z-endoxifen","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atossa Therapeutics \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Quantum Leap Healthcare"}]

    Find Clinical Drug Pipeline Developments & Deals by Atossa Therapeutics

    Menu

    Atossa Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-S...

                            Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.

                            Brand Name : Endoxifen

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 28, 2023

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (...

                            Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.

                            Brand Name : Endoxifen

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2023

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovativ...

                            Details : Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen...

                            Brand Name : Endoxifen

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 23, 2023

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoin...

                            Details : (Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 21, 2023

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atossa Therapeutics Shares Jump 35% Ahead of Data on Endoxifen in Breast Cancer Surgery Patients

                            Details : Endoxifen, an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Endoxifen administered to breast cancer patients prior to surgery.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 07, 2021

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray...

                            Details : The positive assessment by the safety committee allows the study to now enroll the next cohort, which will be the third of a total of four cohorts and the first of two multi-dose, placebo controlled cohorts evaluating AT-301A over AT-301B.

                            Brand Name : AT-301

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 17, 2020

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical St...

                            Details : The Phase 1 study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.

                            Brand Name : AT-301

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 01, 2020

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinic...

                            Details : Atossa has enrolled and first dose of AT-301 in Phase 1 being administered by nasal spray. This group of 8 participants received a single dose of either AT-301A (placebo) or AT-301B (active).

                            Brand Name : AT-301

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 17, 2020

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen

                            Details : The study results show that treatment with Atossa’s proprietary Endoxifen for 20 days prior to unilateral mastectomy and for 18 months after surgery as an adjuvant did not lead to vasomotor symptoms commonly associated with tamoxifen.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 30, 2020

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Atossa Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Avance Clinical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study

                            Details : The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.

                            Brand Name : AT-301

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 22, 2020

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Avance Clinical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth